Irbesartan

Introduction Overview

Generic Name

Irbesartan

Brand Name

Avapro

Dosage Form

Oral tablet (75 mg; 150 mg; 300 mg)

Drug Class

Angiotensin receptor blockers (ARBs)

Pharmacokinetics

Absorption:
Irbesartan is well absorbed orally with peak plasma concentrations typically reached within 1.5 to 2 hours post-dose. Oral bioavailability is relatively high, ranging around 60-80%, reflecting efficient gastrointestinal absorption. Food intake does not significantly affect the rate or extent of absorption, allowing for flexible administration with or without meals. The consistent and predictable absorption profile supports once-daily dosing and stable plasma levels, contributing to effective blood pressure control.

Distribution:
After absorption, irbesartan demonstrates extensive binding to plasma proteins, predominantly albumin, with binding rates of approximately 96%. This high protein binding facilitates wide tissue distribution, including vascular smooth muscle and renal tissue, the primary sites of action. The apparent volume of distribution approximates 53 to 93 liters, indicating distribution beyond the plasma compartment without significant accumulation in adipose tissues. Irbesartan is largely confined to vascular and extracellular fluid compartments.

Metabolism:
Irbesartan undergoes hepatic metabolism primarily via the cytochrome P450 enzyme CYP2C9. Metabolism results in inactive metabolites, with minimal pharmacological activity. Unlike some other ARBs, irbesartan does not undergo significant oxidative metabolism by CYP3A4, reducing interaction potential. Hepatic metabolism proceeds with formation of an inactive glucuronide conjugate and oxidative metabolites, accounting for less than 20% of the administered dose. Polymorphisms in CYP2C9 may modestly affect metabolism rates, but clinical relevance is minimal.

Elimination:
Irbesartan elimination is primarily via biliary-fecal excretion (~80%), with renal clearance accounting for approximately 20%. The elimination half-life ranges between 11 to 15 hours, supporting once-daily dosing. Less than 10% of the administered dose is excreted unchanged in urine. In patients with varying degrees of renal or hepatic impairment, irbesartan's pharmacokinetics remains generally unaffected, although caution is advised. The elimination pattern contributes to a stable therapeutic plasma concentration and a tolerable safety profile.

Dosage Forms

Available Dosage Forms:
- Oral tablet: 75 mg
- Oral tablet: 150 mg
- Oral tablet: 300 mg

Dosages for Adults and Adolescents:
- Hypertension:
- Initial dose: 150 mg orally once daily
- Maintenance dose: 150 mg to 300 mg orally once daily depending on therapeutic response
- Maximum dose: 300 mg once daily
- Diabetic nephropathy (type 2 diabetes with hypertension and proteinuria):
- Recommended dose: 300 mg orally once daily

Specific Patient Populations:
- Pediatric patients (≥6 years old): Use for hypertension is approved, with doses individualized based on patient weight and response; close monitoring advised.
- Patients with renal impairment: No initial dosage adjustment generally required; however, monitoring of renal function and potassium levels is necessary.
- Patients with hepatic impairment: Pharmacokinetic studies show no need for dose adjustment, but caution is recommended.
- Elderly patients: No specific dose adjustments required, but monitoring for hypotension is important due to increased sensitivity.

Mechanism Of Action

Irbesartan is a selective antagonist of the angiotensin II type 1 (AT1) receptor. By selectively blocking the binding of angiotensin II, a potent vasoconstrictor and key player in the renin-angiotensin-aldosterone system (RAAS), irbesartan effectively inhibits the physiological actions of angiotensin II which include vasoconstriction, aldosterone secretion, sodium retention, and sympathetic nervous system activation.

At the molecular level, irbesartan exhibits high affinity for the AT1 receptor subtype present in vascular smooth muscle, adrenal glands, and renal tissue, thereby preventing angiotensin II–mediated signal transduction through G protein-coupled receptor pathways. This blockade decreases intracellular calcium mobilization, leading to relaxation of vascular smooth muscle cells and vasodilation which reduces systemic vascular resistance and lowers blood pressure.

Beyond vasodilation, irbesartan reduces aldosterone-mediated sodium and water retention, thereby decreasing blood volume and making it effective in managing hypertension. Moreover, inhibition of AT1 receptors reduces glomerular hypertension and proteinuria, offering protective effects on renal microvasculature, particularly in patients with diabetic nephropathy.

Compared to angiotensin-converting enzyme inhibitors (ACEIs), irbesartan does not inhibit bradykinin degradation, which may reduce the incidence of bradykinin-related side effects such as cough. Clinical studies demonstrate that irbesartan effectively lowers blood pressure, reduces proteinuria, and slows progression of renal disease in hypertensive patients with type 2 diabetes, substantiating its therapeutic benefit and safety profile in these populations.

Pharmacological Actions

Selective blockade of angiotensin II AT1 receptors leading to vasodilation and decreased systemic vascular resistance
Reduction of aldosterone secretion resulting in decreased sodium and water retention
Decreased sympathetic nervous system activation contributing to lower blood pressure
Renoprotective effects by reducing intraglomerular pressure and proteinuria in diabetic nephropathy
No effect on bradykinin metabolism, reducing risk of cough compared to ACE inhibitors
Antihypertensive effect resulting in lowered systolic and diastolic blood pressure
Improvement of endothelial function by attenuating angiotensin II–mediated oxidative stress
Potential reduction of cardiac remodeling in patients with hypertension
Modulation of inflammatory pathways associated with angiotensin II signaling
Stabilization of renal function in patients with hypertension and type 2 diabetes

Therapeutic Or Clinical Uses

Management of hypertension in adults to reduce blood pressure and cardiovascular risk
Treatment of hypertension in pediatric patients aged 6 years and older
Slowing progression of diabetic nephropathy in patients with type 2 diabetes and hypertension
Renal protection by reducing proteinuria and delaying onset of end-stage renal disease
Potential adjunct therapy in congestive heart failure when combined with other agents
Reduction of the risk of stroke and myocardial infarction through blood pressure control
Use in patients intolerant to ACE inhibitors due to cough or angioedema
Management of patients with high cardiovascular risk and comorbid hypertension
Improvement of vascular compliance and endothelial function
Long-term treatment of hypertensive patients to prevent target organ damage

Side Or Adverse Effects

Dizziness and light-headedness, especially during initiation or dose escalation
Hyperkalemia presenting with symptoms such as muscle weakness, tingling, or arrhythmias
Fatigue or asthenia
Hypotension, particularly in volume-depleted patients
Gastrointestinal symptoms including nausea and dyspepsia
Elevated serum creatinine or changes in renal function
Headache
Allergic reactions, including rash and urticaria
Potential for angioedema, though less common than with ACE inhibitors
Rare reports of syncope and fainting episodes
Upper respiratory tract infections or nasopharyngitis
Back pain
Edema or peripheral swelling
Elevated liver enzymes in rare cases
Reports of chest pain and palpitations

Precautions

Use with caution in patients with impaired renal function or on dialysis
Monitor serum potassium levels to avoid hyperkalemia, especially in combination with potassium-sparing diuretics
Assessment of blood pressure, renal function, and electrolytes should be performed regularly
Caution in patients on low-sodium diets due to risk of hypotension
Avoid concurrent use with aliskiren in patients with diabetes or renal impairment
Use cautiously in patients with a history of angioedema related to previous therapy
Discontinue use immediately if pregnancy is detected
Avoid abrupt discontinuation to prevent rapid increase in blood pressure
Patients prone to volume depletion should be closely monitored to prevent symptomatic hypotension
Consider alternative therapies in patients with bilateral renal artery stenosis
Monitor for signs of allergic reactions in sensitive individuals
Ensure adequate hydration in patients with vomiting, diarrhea, or excessive sweating
Adjust dose cautiously in elderly patients with comorbidities
Evaluate risk-benefit in patients undergoing surgical or diagnostic procedures requiring anesthesia
Educate patients about symptoms of hypotension and hyperkalemia

Warnings

Contraindicated during pregnancy due to risk of fetal injury or death, especially in the second and third trimesters
Do not use with aliskiren-containing medications in diabetic patients or those with compromised kidney function
Risk of symptomatic hypotension in volume- or salt-depleted patients
Potential for hyperkalemia especially when combined with potassium supplements or potassium-sparing diuretics
May cause renal impairment in patients with bilateral renal artery stenosis
Risk of angioedema requiring immediate discontinuation and medical attention
Monitor closely if used in patients with heart failure or renal dysfunction
Caution advised when co-administered with NSAIDs due to risk of renal function deterioration
May cause dizziness; patients should avoid activities requiring mental alertness until effects are known
Not recommended for use during breastfeeding
Hypersensitivity reactions may occur, and drug should be discontinued if they arise
Use cautiously in elderly as they may be more sensitive to blood pressure changes
Avoid rapid dose escalation to minimize adverse cardiovascular events
Report any signs of allergic reactions including swelling or difficulty breathing immediately
Monitor for signs of liver injury or cholestasis although rare

Contraindication

Known hypersensitivity or allergy to irbesartan or any component of the formulation
Pregnancy due to risk of fetal toxicity and death
Concurrent use with aliskiren-containing drugs in patients with diabetes mellitus
Use in patients with a history of angioedema related to previous ARB or ACE inhibitor therapy
Patients with bilateral renal artery stenosis without proper monitoring
Severe hepatic impairment without appropriate dose adjustment and monitoring
Patients with volume depletion or significant hypotension unless corrected prior to therapy
Concomitant use with drugs known to cause hyperkalemia without rigorous monitoring
Children under 6 years of age due to insufficient safety and efficacy data
Concomitant use with other drugs contraindicated due to potential additive adverse effects
Known severe hypersensitivity to other angiotensin II receptor blockers
Any clinical condition where RAAS blockade is contraindicated
Use of irbesartan in combination with ACE inhibitors for dual RAAS blockade is contraindicated in certain populations
Patients on dialysis with unstable hemodynamics without close monitoring
Administration during first trimester of pregnancy due to teratogenic risks

Drug Interactions

Potassium-sparing diuretics, potassium supplements, or salt substitutes can increase risk of hyperkalemia
Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce antihypertensive effects and increase renal toxicity risk
Co-administration with lithium can increase lithium plasma levels and risk of toxicity
Aliskiren is contraindicated in diabetic patients when used with irbesartan due to risk of kidney impairment
Other antihypertensive agents may have additive blood pressure-lowering effects increasing risk of hypotension
Diuretics may enhance hypotensive effects especially during initial therapy
CYP2C9 inhibitors or inducers could theoretically alter irbesartan metabolism though clinical interactions are uncommon
Drugs affecting renal function, such as cyclosporine or tacrolimus, may increase risk of nephrotoxicity
Co-administration with NSAIDs such as ibuprofen, naproxen, and celecoxib is associated with increased risk of renal impairment
Use with drugs that raise serum potassium levels (e.g., heparin, trimethoprim) requires close monitoring
Herbal supplements like St. John's Wort may potentially decrease efficacy due to enzyme induction
Concurrent use with other RAAS inhibitors (ACE inhibitors or other ARBs) may increase adverse effects and requires monitoring
Caution when combined with sympatholytic agents due to potentiation of blood pressure lowering
Interactions with glucose-lowering agents may require monitoring of blood glucose and renal function
Drug interactions may alter pharmacodynamic responses necessitating dose adjustments

Preparations Of The Drug

Avapro oral tablets available in strengths of 75 mg, 150 mg, and 300 mg
Tablets are film-coated, round, and intended for oral administration
Packaged in blister packs or bottles for outpatient use
Store at controlled room temperature, away from excess moisture and heat
Generic formulations available with equivalent dosing strengths
Supplied with patient information leaflets detailing dosing, precautions, and side effects
Not supplied as intravenous or injectable formulation
Some preparations include combination products with hydrochlorothiazide for augmented antihypertensive action
Packaging designed to protect from light and moisture to preserve drug stability
Distributed primarily for prescription use with standardized dosing instructions
Available in standard tablet sizes facilitating dose titration
Manufactured according to strict Good Manufacturing Practices (GMP) standards
Formulations are film-coated to improve swallowing and oral bioavailability
Combination formulations include irbesartan with thiazide diuretics for specific hypertension treatment protocols
Patient adherence aided by convenient once-daily tablet form